Early-stage breast cancer patients not receiving full benefits of chemotherapy


More than half the women suffering from early-stage breast cancer (ESBC) are at increased risk of recurrence or death because of substantial reductions-planned or unplanned-in relative dose-intensity (RDI) when treated with adjuvant chemotherapy, according to a study published in the Journal of Clinical Oncology.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.